EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Regulatory and safety challenges of biosimilars: insights from developed and emerging economies

Prerna Haritwal, Alka Lohani

European Journal of Clinical Pharmacology · 2026-05 · 82 (5)

DOI: 10.1007/s00228-026-04053-3 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Clinical Pharmacology, online erschienen am 15.04.2026. Verfasst von Prerna Haritwal und 1 weiteren Autor:innen. Beteiligte Einrichtung: Amity Institute of Pharmacy, Amity University Uttar Pradesh, Noida, 201313, India. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals. Die Arbeit nennt 96 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Biosimilars offer a cost-effective alternative to originator biologics, but their global adoption remains uneven due to differences in regulatory standards, pharmacovigilance capacity, and healthcare infrastructure. This review compares biosimilar regulatory and safety frameworks in developed (United States, European Union, Japan) and developing (India, Brazil, South Africa) markets to identify key gaps and opportunities for alignment. METHODS: A focused narrative review was conducted using peer-reviewed literature from PubMed, Scopus, and Web of Science complemented by official regulatory guidelines, pharmacovigilance reports, and policy documents published by national and international health authorities. RESULTS: Regulatory agencies in developed economies like FDA, EMA, and PMDA maintain rigorous evaluation processes and robust pharmacovigilance systems. In contrast, developing economies exhibit variability: India, while a major biosimilar producer, faces quality and harmonization challenges; Brazil and South Africa struggle with affordability and infrastructure, limiting uptake. CONCLUSION: The successful integration of biosimilars depends on regulatory maturity, strong pharmacovigilance, and stakeholder awareness. Efforts should focus on harmonizing international standards, strengthening safety monitoring, and improving clinician and patient education. Key takeaways include the need for shared international safety data platforms, the elimination of redundant local bridging studies, and the implementation of pharmacy-level substitution to maximize cost-savings. Harmonization is critical to ensuring equitable access to biologics across diverse economic landscapes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biosimilar PharmaceuticalsHumansPharmacovigilanceDeveloping CountriesDeveloped CountriesDrug and Narcotic ControlUnited StatesDrug Approval

Stichwörter der Autor:innen

BiologicsBiosimilarEuropean UnionImmunogenicityPMDARegulationUSFDA

Substanzen

Biosimilar Pharmaceuticals

Autor:innen und Institutionen

  • Amity Institute of Pharmacy, Amity University Uttar Pradesh, Noida, 201313, India.
  • Amity Institute of Pharmacy, Amity University Uttar Pradesh, Noida, 201313, India. alkalohani06@gmail.com.

Zitieren

APA

Haritwal, P., & Lohani, A. (2026). Regulatory and safety challenges of biosimilars: insights from developed and emerging economies. European Journal of Clinical Pharmacology, 82(5). https://doi.org/10.1007/s00228-026-04053-3

Vancouver

Haritwal P, Lohani A. Regulatory and safety challenges of biosimilars: insights from developed and emerging economies. European Journal of Clinical Pharmacology. 2026;82(5). doi:10.1007/s00228-026-04053-3

BibTeX
@article{Haritwal2026,
  author = {Haritwal, Prerna and Lohani, Alka},
  title = {Regulatory and safety challenges of biosimilars: insights from developed and emerging economies},
  journal = {European Journal of Clinical Pharmacology},
  year = {2026},
  volume = {82},
  number = {5},
  doi = {10.1007/s00228-026-04053-3}
}
Kostenlos starten →